FierceBiotech 9. März 2026 Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China
FierceBiotech 9. März 2026 BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3
FierceBiotech 9. März 2026 Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
FierceBiotech 9. März 2026 Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
FierceBiotech 9. März 2026 Why early developability assessment is a strategic necessity in modern antibody discovery
FierceBiotech 6. März 2026 FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
FierceBiotech 6. März 2026 Beam rejigs deal to retain base editing technology amid partner's dissolution
FierceBiotech 6. März 2026 Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda
FierceBiotech 6. März 2026 Senior FDA official refutes uniQure's claims amid controversy over Huntington's gene therapy
FierceBiotech 6. März 2026 Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
FierceBiotech 6. März 2026 Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug